2024

1. Exploring current and emerging therapies for porphyrias

   Liver International, Vol. 44, Núm. 9, pp. 2174-2190

2. Non-mitogenic FGF19 mRNA-based therapy for the treatment of experimental metabolic dysfunction-associated steatotic liver disease (MASLD)

   Clinical science (London, England : 1979), Vol. 138, Núm. 20, pp. 1265-1284

3. Porfirias.

   Medicina interna (Elsevier España), pp. 1865-1873

4. Porphyrins and the porphyrias

   Liver International

5. Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates

   Gut

6. The Alpha-Lipoic Acid Improves Glucose Metabolism and Hyperinsulinemia in Acute Intermittent Porphyria: A Nutritional Concept for the Management of Rare Disorders

   Cellular and Molecular Gastroenterology and Hepatology